BackLite Strategy Overview

Lite Strategy EBIT

Lite Strategy's EBIT is $-58M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$21.61M
↓ 679.02% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$57.99M
↓ 155.95% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Lite Strategy (LITS) FAQ

The latest EBIT for LITS is $-58M as of March 2026. That compares with $-23M in the prior-year period — down 156.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Lite Strategy's historical trend and sector peers before judging valuation or financial health.

Over the past year, LITS's EBIT moved from $-23M to $-58M — a 156.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lite Strategy's operating scale or balance-sheet position.

Against Healthcare companies, LITS currently prints $-58M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Lite Strategy's growth, margins, and balance sheet.

A EBIT figure of $-58M for LITS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting LITS's EBIT ($-58M), review year-over-year change from $-23M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.